

Supplementary Table S5. Clinical and molecular data of RA patients non-naïve to b/tsDMARDs at TNFi initiation (Cohort 4).

Clinical parameters	RA non-naïve patients starting TNFi (n=30)	3-months (n=30)	6-months (n=29)	12-months (n=21)
Male/Female (n/n)	7/23	-	-	-
Age, years (mean ± SD)	51.40 ± 10.76	-	-	-
Disease evolution, years (mean ± SD)	11.17 ± 8.54	-	-	-
TJC (mean ± SD)	7.63 ± 5.87	2.63 ± 5.67**	1.61 ± 2.50****	2.75 ± 6.35***
SJC (mean ± SD)	4.43 ± 4.20	1.50 ± 4.35*	1.11 ± 2.13**	0.50 ± 1.00**
DAS28-CRP (mean ± SD)	4.61 ± 1.02	2.87 ± 1.47****	2.99 ± 0.90****	2.76 ± 1.32****
SDAI (mean ± SD)	27.49 ± 9.75	13.95 ± 14.22***	13.68 ± 6.90****	13.01 ± 11.06**
CDAI (mean ± SD)	26.23 ± 9.44	12.90 ± 13.03***	12.45 ± 7.03****	12.35 ± 10.88**
HAQ (mean ± SD)	0.98 ± 0.45	0.97 ± 0.41	0.83 ± 0.55	0.66 ± 0.37
Smoking (n, %)	9, 30.00%	-	-	-
Hypertension (n, %)	4, 13.33%	-	-	-
Laboratory parameters				

CRP, mg/mL (mean ± SD)	12.58 ± 18.93	10.49 ± 21.41	9.23 ± 12.77	6.93 ± 9.01
ESR, mm/h (mean ± SD)	20.31 ± 18.30	15.67 ± 17.28	16.17 ± 11.19	11.79 ± 11.12
ACPAs positivity (n, %)	23, 76.67%	10, 33.33%	20, 66.67%	12, 40.00%
RF positivity (n, %)	18, 60.00%	19, 63.33%	20, 66.67%	12, 40.00%
Treatments				
Corticosteroids (n, %)	27, 90.00%	-	-	-
cDMARDs (n, %)	23, 76.67%	-	-	-
TNFi (n, %)	15, 50.00%	-	-	-
IL6Ri (n, %)	3, 10.00%	-	-	-
JAKi (n, %)	10, 33.33%	-	-	-
CTLA4 (n, %)	2, 6.67%	-	-	-
Anti-CD20 (n, %)	0, 0.00%	-	-	-

TJC (Tender Joint Count); SJC (Swollen Joint Count); DAS28-CRP (Disease Activity Score); SDAI (Simplified Disease Activity Index); CDAI (Clinical Disease Activity Index); HAQ (Health Assessment Questionnaire); CRP (C-reactive protein); ESR (Erythrocyte sedimentation rate)); ACPA (Anti-citrullinated protein antibodies); RF (Rheumatoid Factor); cDMARD (Conventional DMARDs); TNFi (Tumor necrosis factor inhibitor); IL6Ri

(Interleukin-6 Receptor Inhibitor); JAKi (Janus kinase inhibitor); CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4). Statistical significance levels respect to baseline time were designated as follows: (****) <0.0001 p-value; (***) <0.001 p-value; (**) <0.01 p-value; (*) <0.05 p-value.